We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pathogens and Antibiotic Resistance Detected in Implant/Tissue Infections

By LabMedica International staff writers
Posted on 03 Oct 2012
Scientists from two companies are collaborating to develop a molecular diagnostics solution for detection of pathogens and antibiotic resistance in implant and tissue infections (ITI).

One important application for the platform will be in orthopedics e.g., knee and hip replacement surgeries. More...
A new ITI cartridge, Unyvero, is being developed not only for general surgery, but also for infections caused by biofilms (e.g., on knee and hip implants or catheters), and for abdominal surgery infections, diabetic foot, burn wounds etc.

Curetis AG (Holzgerlingen, Germany) and Heraeus Medical GmbH (Hanau, Germany) signed a collaboration agreement to jointly develop the Unyvero cartridge for the detection of the cause of infections as well as antibiotic resistances of organisms involved in ITI. The resulting Unyvero cartridge and application will be a Curetis-labeled IVD.

The CE-marked Unyvero System is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.

For development of the new cartridge, the two companies conducted market research in orthopedic applications throughout Europe. They also met with clinicians in Germany, Switzerland, France, the UK, and Scandinavia to determine the pathogens and antibiotic resistances that need to be included in the diagnostic panel of the cartridge.

The partners expect assay development for the new cartridge to be completed by early 2013, with clinical validation and CE marking throughout 2013 and an expected launch in the EU by the end of 2013. The product is will probably include more than 40 and possibly up to 50 analytes.

Currently it takes from 7-15 days to obtain results from biofilm samples. This often leads to prolonged treatment, repeated surgeries and increased morbidity and healthcare costs. Oliver Schacht, CEO of Curetis, said, “We offer highly multiplexed analyte panels of pathogens and resistance markers for applications that require the ability to work with a diverse set of native, complex clinical samples and an unmatched ease of use from sample-to-result in about 4 hours.”

Related Links:

Curetis AG
Heraeus Medical GmbH






Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
HPV Test
Allplex HPV28 Detection
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.